小金丸对慢性非细菌性前列腺炎疼痛作用的临床与实验研究
|
摘要
目的:运用小金丸治疗慢性非细菌性前列腺炎,从临床和实验方面对其缓解慢性非细菌性前列腺炎疼痛症状的机理进行探讨。
方法:临床研究:将80例痰湿瘀阻型慢性非细菌性前列腺炎患者采用随机、对照的方法,分为治疗组40例,对照组40例,分别给予小金丸和塞来昔布胶囊治疗,疗程4周,观察慢性前列腺炎疼痛症状评分的变化情况。实验研究:采用冰乙酸致小鼠扭体实验,将小鼠随机分为空白组、对照组(塞来昔布胶囊组)、小金丸高、中、低剂量组,观察其对小鼠扭体抑制情况;采用大鼠前列腺腹叶注射完全弗氏佐剂(CFA)致慢性非细菌性前列腺炎疼痛模型,设立空白组、模型组、对照组(塞来昔布胶囊组)、小金丸高、中、低剂量组,用药4周,免疫组化法并结合图形图像分析系统检测前列腺组织NGF、COX-2表达的变化。
结果:小金丸治疗组患者前列腺疼痛症状评分明显降低(P＜0.05);小金丸显著减少冰乙酸致小鼠扭体的次数(P＜0.01);小金丸高、中剂量组及对照组较模型组NGF、COX-2表达明显降低(P＜0.01)。
结论:小金丸对慢性非细菌性前列腺炎疼痛症状有一定的缓解作用:小金丸对小鼠有显著的镇痛作用:小金丸可抑制慢性非细菌性前列腺炎疼痛模型大鼠前列腺组织NGF、COX-2的表达,并可能通过此抑制作用而达到缓解疼痛的目的。
Objectives:To assess the efficacy of Xiaojin Wan in the treatment of the chronic nonbacterial prostatitis and explore the mechanism of alleviating the prostatitis pain from clinical and experimental aspect.
Methods:Clinical study:80 patients suffered from CNP were randomly divided into two groups,40 cases in the treatment group received Xiaojin Wan and 40 cases in the control group received Celecoxib Capsules.The research duration was 4 weeks.CPSI scale was used to evaluate the efficacy.Experiment research:Use glacial acetic acid induced rats writhing test.The rats were divided into five groups:blank group,control group(Celecoxib Capsules group),Xiaojin Wan high/middle/low dose group.Observe the restraining result of the writhen rats.The chronic nonbacterial prostatitis pain model rats were injected Complete Freund's adjuvant(CFA) into the ventral part of prostate.These rats were divided into six groups:blank group,model group,control group(Celecoxib Capsules group),Xiaojin Wan high/middle/low dose group.After 4 weeks' research duration,detect the changes of NGF and COX-2 expression in the prostate tissue with immunohistochemical technique and graphics video analysis system.
Results:The average scores of pain symptom in CPSI scale of Xiaojin Wan group decreased;Xiaojin Wan can significantly reduce the frequency of glacial acetic acid induced rats writhing;The expression of NGF and COX-2 in the chronic nonbacterial prostatitis pain rats' prostate tissues was as follows:Xiaojin Wan high dose group,middle dose group and the control group were significantly lower than the model group(P＜0.01).
Conclusions:Xiaojin Wan can alleviate the chronic nonbacterial prostatitis pain,and has a remarkable analgesic function;Xiaojin Wan may alleviate the chronic nonbacterial prostatitis pain by inhibiting the expression of NGF and COX-2 in prostate tissue.
方法:临床研究:将80例痰湿瘀阻型慢性非细菌性前列腺炎患者采用随机、对照的方法,分为治疗组40例,对照组40例,分别给予小金丸和塞来昔布胶囊治疗,疗程4周,观察慢性前列腺炎疼痛症状评分的变化情况。实验研究:采用冰乙酸致小鼠扭体实验,将小鼠随机分为空白组、对照组(塞来昔布胶囊组)、小金丸高、中、低剂量组,观察其对小鼠扭体抑制情况;采用大鼠前列腺腹叶注射完全弗氏佐剂(CFA)致慢性非细菌性前列腺炎疼痛模型,设立空白组、模型组、对照组(塞来昔布胶囊组)、小金丸高、中、低剂量组,用药4周,免疫组化法并结合图形图像分析系统检测前列腺组织NGF、COX-2表达的变化。
结果:小金丸治疗组患者前列腺疼痛症状评分明显降低(P＜0.05);小金丸显著减少冰乙酸致小鼠扭体的次数(P＜0.01);小金丸高、中剂量组及对照组较模型组NGF、COX-2表达明显降低(P＜0.01)。
结论:小金丸对慢性非细菌性前列腺炎疼痛症状有一定的缓解作用:小金丸对小鼠有显著的镇痛作用:小金丸可抑制慢性非细菌性前列腺炎疼痛模型大鼠前列腺组织NGF、COX-2的表达,并可能通过此抑制作用而达到缓解疼痛的目的。
Objectives:To assess the efficacy of Xiaojin Wan in the treatment of the chronic nonbacterial prostatitis and explore the mechanism of alleviating the prostatitis pain from clinical and experimental aspect.
Methods:Clinical study:80 patients suffered from CNP were randomly divided into two groups,40 cases in the treatment group received Xiaojin Wan and 40 cases in the control group received Celecoxib Capsules.The research duration was 4 weeks.CPSI scale was used to evaluate the efficacy.Experiment research:Use glacial acetic acid induced rats writhing test.The rats were divided into five groups:blank group,control group(Celecoxib Capsules group),Xiaojin Wan high/middle/low dose group.Observe the restraining result of the writhen rats.The chronic nonbacterial prostatitis pain model rats were injected Complete Freund's adjuvant(CFA) into the ventral part of prostate.These rats were divided into six groups:blank group,model group,control group(Celecoxib Capsules group),Xiaojin Wan high/middle/low dose group.After 4 weeks' research duration,detect the changes of NGF and COX-2 expression in the prostate tissue with immunohistochemical technique and graphics video analysis system.
Results:The average scores of pain symptom in CPSI scale of Xiaojin Wan group decreased;Xiaojin Wan can significantly reduce the frequency of glacial acetic acid induced rats writhing;The expression of NGF and COX-2 in the chronic nonbacterial prostatitis pain rats' prostate tissues was as follows:Xiaojin Wan high dose group,middle dose group and the control group were significantly lower than the model group(P＜0.01).
Conclusions:Xiaojin Wan can alleviate the chronic nonbacterial prostatitis pain,and has a remarkable analgesic function;Xiaojin Wan may alleviate the chronic nonbacterial prostatitis pain by inhibiting the expression of NGF and COX-2 in prostate tissue.
引文
[1]何乐业.前列腺炎综合征[J].中华泌尿外科杂志,2000,21:697-699.
[2]Litwin MS,McNaughton-Collins M,Fowler FJ Jr,et al.J Urol 1999;162:369-375.
[3]郭应禄,李宏军,主编.前列腺炎[M].北京:人民军医出版社,2002:88-97.
[4]Wenninger K,Heiman JR,Rothman I,et a.l,Sickness impact of chronic nonbacterial prostatitis and its correlates.J Urol.1996;155(3):965-8.
[5]R.Melzack&P.D.Wall著,王兆麟等译.疼痛的挑战,第一版.西安:陕西科技出版社,1990:257.
[6]Nickel CJ.Can.J Urol,2000;7(5):1091-1098.
[7]Nickel JC.Prostatis:Evolving management strategies[J].Urol Clin North Am,1999,26(4):737-751.
[8]Hakenberg OW,Wirth MP.Urol Int 2002;68:138-143.
[9]Dimitrakov J,Diemer T,Ludwig M,et al,Curr Opin,Urol 2001;11:87-91.
[10]Krieger JN,Riley DE.J Urol 2002;167;2574-258313 Krieger JN,Riley DE.lilt J Antimicrob Agents 2002;19:475479
[11]Zermann DH,ishigooka M,Doggweiler-Wiygul R,et al.World J Urol,2001,19:173-179.
[12]Barbalias GA,Nildforidis G,Liatsikos EN.J Uro1,1998;159:883-887.
[13]曲晓伟,张蜀武,张培海,等.慢性前列腺炎疼痛症状与炎性介质相关性研究进展[J].中国疼痛医学杂志,2006,12(6):363-364.
[14]吴良村.癌痛的中医药治疗[J].浙江中西医结合杂志,2000,10(1):1-2.
[15]徐淑云主编.药理实验方法学.第三版.北京:人民卫生出版社.2002.
[16]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究[J].第三军医大学学报,2005,27(18):1853-1854.
[17]隋·巢元方.诸病源候论.淋病诸候.北京:人民卫生出版社.1955.
[18]元·朱震亨.丹溪心法.淋.北京:人民卫生出版社.1993.
[19]素问·痿论篇.北京:人民卫生出版社.1963.
[20]明·张介宾.景岳全书·淋浊.上海:上海科学技术出版社.1959.
[21]王祖贤.慢性前列腺炎治疗重在活血化瘀[J].湖北中医杂志,17(2):49.
[22]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究[J].中国中西医结合杂志,1998,18(9):534-535.
[23]刘春英,赵树森.施汉章治疗慢性前列腺炎经验[J].中医杂志,1992,33(10):21.
[24]Drach GW,Fair WR,Meares EM,et al.classification of benign diseases associated with prostatic pain:pmstatitis or prodtatodynia.J Urol,1978,120:266.
[25]Krieger JN,Nyberg 1,Nickel JC.NIH consensus definition and classification of prostatitis.JAMA,1999.
[26]Clinical Effectiveness Group(UK).National guidecine for the management ofproststitis.Sex TransmInfect,1999,75:46-50.
[27]鲍镇美.前列腺内尿液返流与前列腺炎[J].中华泌尿外科杂志,1995,16(6):380.
[28]Barbaias GA,Nildforidis g,Liatsikos EN.Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics.J Urol,1998,159(3):883-887.
[29]Yasumoto R,Kawano M,Tsujinot.et al.seminal plasma cytokines in nonbacterial prostatitis.Acta Urol Belg,1995,41:771-774.
[30]赵天恩,徐文严.慢性前列腺炎的研究进展[J].国外医学.皮肤性病学分册,2002,28(3):139-142.
[31]唐孝达.慢性前列腺炎诊断与治疗进展[J].中国男科学杂志,2002,16(3):193-196.
[32]Gurunadha Rao Tunuguntla HS,Evans CP.Management of prostatitis[J].Prostate Cancer Prostatic Dis,2002,5(3):172-179.
[33]Goldenberg MM.Celecoxib,a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis[J].Clin Ther,1999,21(9):1497-1513.
[34]叶章群,曾晓勇.慢性前列腺炎诊疗进展[J].中华男科学,2003,9(7):483-488.
[35]倪梁朝,陈伟星,李贤新,等.特异性环氧化酶一2抑制剂治疗慢性盆腔疼痛综合症的临床研究[J].中华现代医学杂志,2004,14(12):92-94.
[36]Nickel JC,Pontari M,Moon T,et al.A randomized,placebo controlled,multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis[J].J Urol,2003,169(4):1401 - 1405.
[37]Wesselmann U.Neurogertic inflammation and chronic pelvic pain.World J Urol,2001,19:180-185.
[38]Anabu I,Dirk-henrik Z,Ragi D,et al.Similarity of distributions of spinal C-fos and plasma extravasation after acute chemical irritation of the bladder and the prostate.J Urol,2000,164:1751-1756.
[39]王秀丽.阿片肽及糖皮质激素与疼痛的神经免疫调节[J].中华老年多器官疾病杂志.2005,4(2):141-144.
[40]Iwata T,Ukimura O,Inaba M,et al.Immunohistochemical studies on the distribution of nerve fibers in the human prostate with special reference to the anterior fibro muscular stroma[J].Prostate,2001,'48(4):242.
[41]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J].Urology,2002,59(4):603.
[42]Zermarm ZH,Ishigooka GA,Weiler RD.Neurourological insights into the etiology of genitourinary pain in men[J].JUrol,1999,161(3):903.
[43]Zermann DH,Ishigooka M,Doggweiler R,et al.The male chronic pelvic pain syndrome[J].World J Urol,2001,19:173.
[44]Miller LJ,Fischer KA,Goralnick SJ.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J].Urology,2002,59(4):603.
[45]Woolf,C.J.and Thompson,S.W.:The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation;implications for the treatment of post-injury pain hypersensitivity states.Pain,1991,44:293-298.
[46]Tusjii M,Dubois RN.Alteration in cellar adhesion and apoptosis in epithelial cells overexpressing prostsglandin endoperoxide synthase-2.Cell,1995;83:49.
[47]赵聪敏,温恩懿.脑缺氧缺血损伤过程中环氧合酶2的作用及机制[J].中国临床康复,2004,8(7):1328-9.
[48]朱辉,杨增明.环氧合酶的研究进展[J].生理科学进展,2004,35(1):81.
[49]汪丙昂,李改丽.环氧合酶2的神经生物学作用[J].中国临床康复,2005,9(33):133-135.
[50]Hidley SH,Sarafied SJ,Lee JC,et al.Actions of IL-1 are selectively controlled by P38 mitogen-actived protein kinase.J Immunol,1997;158:3165.
[51]高鹏,周君,白海燕.COX-2及其选择性抑制剂的研究现状与展望[J].天津药学,2002,14(2):25-26.
[52]Davies P,Bailey PJ,Goldenberg MM,et al.The role of arachidonic acid oxygenation products in pain and inflammation.Annu Rev Immunol,1984;2:335-57.
[53]Offenbacher S,Heasman PA,Collins JG,et al.Modulation of host PGE2secretion as a determinant of periodontal disease expression[J].J Periodontol,1993;64:432-44.
[54]王勤章,王蓉,丁国富,等.膀胱癌中环氧化酶一2的表达与临床病理的关系.中国现代医学杂志[J],2003,13(20):32-34.
[55]Shahed AR,Shoskes DA.Correlation of β-endorphin and proslagla- ndin E2levels in prostatic fluid of patients with Chronic prostatitis with diagnosis and treatment response[J].J Urol,2001,66:1738.
[1]Nickel CJ.Prostatitis syndromes:an update for urologic practice.Can-J-Urol.2000,7(5):1091-1098.
[2]Wesselmann U.Neurogenic inflammation and chronic pelvic pain.World J Urol,2001,19:180-185.
[3]Lin Q,Wu J,Willis WD.Dorsal root reflexes and cutaneous neurogenic inflammation after intradermal injection of capsaicin in rats.J Neurophysiol,1999,82:2602-2611.
[4]Rocacci P,Marcesca M.Referred pain from somatic and visceral structures.Curt RevPain,1999,3:96-99.
[5]Anabu I,Dirk-henrik Z,Ragi D,et al.Similarity of distributions of spinal C-fos and plasma extravasation after acute chemical irritation of the bladder and the prostate.J Urol,2000,164:1751-1756.
[6]Woolf,C.J.and Thompson,S.W.:The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation;Implications for the treatment of post-injury pain hypersensitivity states.Pain,1991,44:293-298.
[7]Keast,J.R.and Kepper,M.E.:Differential regulation of trkA and p75 in noradrenergic pelvic autonomic ganglion cells after deafferentation of their cholinergic neighbours.Eur J Neurosci,2001,13:211.
[8]Meusburger,S.M.and Keast,J.R.:Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion ceils in vitro.Neuroscience,2001,108:331-335.
[9]Shelbume,C.P.and Ryan,J.:The role of Th2 cytokines in mast cell homeostasis.Immunol Rev,2001,179:82-86.
[10]Lee JC,Yang CC,Kromm BG,et al.Neurophysiologic testing in chronic pelvic pain syndrome:a pilot study.Urol,2001;58(2):246-249.
[11]Pasqualotto FF,Sharma RK,Potts JM,et al.Seminal oxidative stress in patients with chronic prostatitis.Urol,2000;55(6):881-885.
[12]刘小平,邓岩.氧自由基在前列腺炎发病中的作用.中华男科学杂志,2001;15(4):264-266.
[13]Zermann DH;Ishigooka M;Doggweiler R,et al.The male chronic pelvic pain syndrome.World J Urol.2001,19(3):173-179.
[14]Shahed AR,Shoskes DA.Correlation of 13-endorphin and prostaglandin E2levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001;166:1738-1741.
[15]宋波,金锡御,刘志平.功能性膀胱下尿路梗阻与前列腺炎.中华泌尿外科杂志,1995,16(2):78.
[16]Clemens JQ,Nadler RB,Schaeffer AJ.Biofeedback,pelvic floor re-education,and bladder training for male chronic pelvic pain syndrome.Urology,2000,56:951-955.
[17]Zermann DH;Ishigooka M;Doggweiler R,et al.The male chronic pelvic pain syndrome.World J Urol.2001,19(3):173-179.
[18]Zermann DH,Doggweiler R,Ishigooka M,et al.Male pelvic pain-a neuro-behavioral perspective.Neurourol Urodyn,1998,17:441.
[19]De la Rosette JJ,Karthaus HF,van Kerrebroeck PE,de Boo T,Debruyne FM.Research in 'prostatitis syndromes':the use of alfuzosin(a new alphal-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirrned urodynamic abnormalities.Eur Urol 1992;22:222-227.
[20]Alexander,R.B.,Ponniah,S.,Hasday,J.and Hebel,J.R;Elevated levels of proinfl-ammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52:744-749.
[21]Orhan,I,Onur,R,Ilhan,N.and Ardicoglu,A:Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome,hat J Urol,2001,8:495-501.
[22]Nishimura,T.,Abe,H.,Ito,H.,Ikeda,K.,Oka,E and Yamamoto,M.:IL-lra versus IL-1 levels in prostatic fluid from prostati.tis patients.Urol Int,1998,60:92-96.
[23]Miller,L.J.,Fischer,K.A.,Goralnick,S.J.,Litt,M.,Burleson,J.A.,Albertsen,P.et al:Intefleukin-10 levels in seminal plasma:implications for chronic prostatitis chronic pelvic pain syndrome.J Urol,2002,167:753-759.
[24]Fiorentino,D.E,Bond,M.W.and Mosmann,T.R.:Two types of mouse T helper cell.IV.Th2 clones secrete a factor that inhibits cytokine production by Thl clones.J Exp Med,1989,170:2081-2084.
[25]Baggiolini,M.,Walz,A.and Kunkel,S.L.:Neutrophil-activating peptide- 1/interleukin 8,a novel cytokine that activates neutrophils.J Clin Invest,1989,84:1045-1048.
[26]唐孝达.慢性前列腺炎诊断与治疗进展[J].中国男科学杂志,2002,16(3):193-196.
[2]Litwin MS,McNaughton-Collins M,Fowler FJ Jr,et al.J Urol 1999;162:369-375.
[3]郭应禄,李宏军,主编.前列腺炎[M].北京:人民军医出版社,2002:88-97.
[4]Wenninger K,Heiman JR,Rothman I,et a.l,Sickness impact of chronic nonbacterial prostatitis and its correlates.J Urol.1996;155(3):965-8.
[5]R.Melzack&P.D.Wall著,王兆麟等译.疼痛的挑战,第一版.西安:陕西科技出版社,1990:257.
[6]Nickel CJ.Can.J Urol,2000;7(5):1091-1098.
[7]Nickel JC.Prostatis:Evolving management strategies[J].Urol Clin North Am,1999,26(4):737-751.
[8]Hakenberg OW,Wirth MP.Urol Int 2002;68:138-143.
[9]Dimitrakov J,Diemer T,Ludwig M,et al,Curr Opin,Urol 2001;11:87-91.
[10]Krieger JN,Riley DE.J Urol 2002;167;2574-258313 Krieger JN,Riley DE.lilt J Antimicrob Agents 2002;19:475479
[11]Zermann DH,ishigooka M,Doggweiler-Wiygul R,et al.World J Urol,2001,19:173-179.
[12]Barbalias GA,Nildforidis G,Liatsikos EN.J Uro1,1998;159:883-887.
[13]曲晓伟,张蜀武,张培海,等.慢性前列腺炎疼痛症状与炎性介质相关性研究进展[J].中国疼痛医学杂志,2006,12(6):363-364.
[14]吴良村.癌痛的中医药治疗[J].浙江中西医结合杂志,2000,10(1):1-2.
[15]徐淑云主编.药理实验方法学.第三版.北京:人民卫生出版社.2002.
[16]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究[J].第三军医大学学报,2005,27(18):1853-1854.
[17]隋·巢元方.诸病源候论.淋病诸候.北京:人民卫生出版社.1955.
[18]元·朱震亨.丹溪心法.淋.北京:人民卫生出版社.1993.
[19]素问·痿论篇.北京:人民卫生出版社.1963.
[20]明·张介宾.景岳全书·淋浊.上海:上海科学技术出版社.1959.
[21]王祖贤.慢性前列腺炎治疗重在活血化瘀[J].湖北中医杂志,17(2):49.
[22]张亚强,刘猷枋.前列腺方治疗慢性前列腺炎血瘀证的临床与实验研究[J].中国中西医结合杂志,1998,18(9):534-535.
[23]刘春英,赵树森.施汉章治疗慢性前列腺炎经验[J].中医杂志,1992,33(10):21.
[24]Drach GW,Fair WR,Meares EM,et al.classification of benign diseases associated with prostatic pain:pmstatitis or prodtatodynia.J Urol,1978,120:266.
[25]Krieger JN,Nyberg 1,Nickel JC.NIH consensus definition and classification of prostatitis.JAMA,1999.
[26]Clinical Effectiveness Group(UK).National guidecine for the management ofproststitis.Sex TransmInfect,1999,75:46-50.
[27]鲍镇美.前列腺内尿液返流与前列腺炎[J].中华泌尿外科杂志,1995,16(6):380.
[28]Barbaias GA,Nildforidis g,Liatsikos EN.Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics.J Urol,1998,159(3):883-887.
[29]Yasumoto R,Kawano M,Tsujinot.et al.seminal plasma cytokines in nonbacterial prostatitis.Acta Urol Belg,1995,41:771-774.
[30]赵天恩,徐文严.慢性前列腺炎的研究进展[J].国外医学.皮肤性病学分册,2002,28(3):139-142.
[31]唐孝达.慢性前列腺炎诊断与治疗进展[J].中国男科学杂志,2002,16(3):193-196.
[32]Gurunadha Rao Tunuguntla HS,Evans CP.Management of prostatitis[J].Prostate Cancer Prostatic Dis,2002,5(3):172-179.
[33]Goldenberg MM.Celecoxib,a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis[J].Clin Ther,1999,21(9):1497-1513.
[34]叶章群,曾晓勇.慢性前列腺炎诊疗进展[J].中华男科学,2003,9(7):483-488.
[35]倪梁朝,陈伟星,李贤新,等.特异性环氧化酶一2抑制剂治疗慢性盆腔疼痛综合症的临床研究[J].中华现代医学杂志,2004,14(12):92-94.
[36]Nickel JC,Pontari M,Moon T,et al.A randomized,placebo controlled,multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis[J].J Urol,2003,169(4):1401 - 1405.
[37]Wesselmann U.Neurogertic inflammation and chronic pelvic pain.World J Urol,2001,19:180-185.
[38]Anabu I,Dirk-henrik Z,Ragi D,et al.Similarity of distributions of spinal C-fos and plasma extravasation after acute chemical irritation of the bladder and the prostate.J Urol,2000,164:1751-1756.
[39]王秀丽.阿片肽及糖皮质激素与疼痛的神经免疫调节[J].中华老年多器官疾病杂志.2005,4(2):141-144.
[40]Iwata T,Ukimura O,Inaba M,et al.Immunohistochemical studies on the distribution of nerve fibers in the human prostate with special reference to the anterior fibro muscular stroma[J].Prostate,2001,'48(4):242.
[41]Miller LJ,Fischer KA,Goralnick SJ,et al.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J].Urology,2002,59(4):603.
[42]Zermarm ZH,Ishigooka GA,Weiler RD.Neurourological insights into the etiology of genitourinary pain in men[J].JUrol,1999,161(3):903.
[43]Zermann DH,Ishigooka M,Doggweiler R,et al.The male chronic pelvic pain syndrome[J].World J Urol,2001,19:173.
[44]Miller LJ,Fischer KA,Goralnick SJ.Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J].Urology,2002,59(4):603.
[45]Woolf,C.J.and Thompson,S.W.:The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation;implications for the treatment of post-injury pain hypersensitivity states.Pain,1991,44:293-298.
[46]Tusjii M,Dubois RN.Alteration in cellar adhesion and apoptosis in epithelial cells overexpressing prostsglandin endoperoxide synthase-2.Cell,1995;83:49.
[47]赵聪敏,温恩懿.脑缺氧缺血损伤过程中环氧合酶2的作用及机制[J].中国临床康复,2004,8(7):1328-9.
[48]朱辉,杨增明.环氧合酶的研究进展[J].生理科学进展,2004,35(1):81.
[49]汪丙昂,李改丽.环氧合酶2的神经生物学作用[J].中国临床康复,2005,9(33):133-135.
[50]Hidley SH,Sarafied SJ,Lee JC,et al.Actions of IL-1 are selectively controlled by P38 mitogen-actived protein kinase.J Immunol,1997;158:3165.
[51]高鹏,周君,白海燕.COX-2及其选择性抑制剂的研究现状与展望[J].天津药学,2002,14(2):25-26.
[52]Davies P,Bailey PJ,Goldenberg MM,et al.The role of arachidonic acid oxygenation products in pain and inflammation.Annu Rev Immunol,1984;2:335-57.
[53]Offenbacher S,Heasman PA,Collins JG,et al.Modulation of host PGE2secretion as a determinant of periodontal disease expression[J].J Periodontol,1993;64:432-44.
[54]王勤章,王蓉,丁国富,等.膀胱癌中环氧化酶一2的表达与临床病理的关系.中国现代医学杂志[J],2003,13(20):32-34.
[55]Shahed AR,Shoskes DA.Correlation of β-endorphin and proslagla- ndin E2levels in prostatic fluid of patients with Chronic prostatitis with diagnosis and treatment response[J].J Urol,2001,66:1738.
[1]Nickel CJ.Prostatitis syndromes:an update for urologic practice.Can-J-Urol.2000,7(5):1091-1098.
[2]Wesselmann U.Neurogenic inflammation and chronic pelvic pain.World J Urol,2001,19:180-185.
[3]Lin Q,Wu J,Willis WD.Dorsal root reflexes and cutaneous neurogenic inflammation after intradermal injection of capsaicin in rats.J Neurophysiol,1999,82:2602-2611.
[4]Rocacci P,Marcesca M.Referred pain from somatic and visceral structures.Curt RevPain,1999,3:96-99.
[5]Anabu I,Dirk-henrik Z,Ragi D,et al.Similarity of distributions of spinal C-fos and plasma extravasation after acute chemical irritation of the bladder and the prostate.J Urol,2000,164:1751-1756.
[6]Woolf,C.J.and Thompson,S.W.:The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation;Implications for the treatment of post-injury pain hypersensitivity states.Pain,1991,44:293-298.
[7]Keast,J.R.and Kepper,M.E.:Differential regulation of trkA and p75 in noradrenergic pelvic autonomic ganglion cells after deafferentation of their cholinergic neighbours.Eur J Neurosci,2001,13:211.
[8]Meusburger,S.M.and Keast,J.R.:Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion ceils in vitro.Neuroscience,2001,108:331-335.
[9]Shelbume,C.P.and Ryan,J.:The role of Th2 cytokines in mast cell homeostasis.Immunol Rev,2001,179:82-86.
[10]Lee JC,Yang CC,Kromm BG,et al.Neurophysiologic testing in chronic pelvic pain syndrome:a pilot study.Urol,2001;58(2):246-249.
[11]Pasqualotto FF,Sharma RK,Potts JM,et al.Seminal oxidative stress in patients with chronic prostatitis.Urol,2000;55(6):881-885.
[12]刘小平,邓岩.氧自由基在前列腺炎发病中的作用.中华男科学杂志,2001;15(4):264-266.
[13]Zermann DH;Ishigooka M;Doggweiler R,et al.The male chronic pelvic pain syndrome.World J Urol.2001,19(3):173-179.
[14]Shahed AR,Shoskes DA.Correlation of 13-endorphin and prostaglandin E2levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response.J Urol,2001;166:1738-1741.
[15]宋波,金锡御,刘志平.功能性膀胱下尿路梗阻与前列腺炎.中华泌尿外科杂志,1995,16(2):78.
[16]Clemens JQ,Nadler RB,Schaeffer AJ.Biofeedback,pelvic floor re-education,and bladder training for male chronic pelvic pain syndrome.Urology,2000,56:951-955.
[17]Zermann DH;Ishigooka M;Doggweiler R,et al.The male chronic pelvic pain syndrome.World J Urol.2001,19(3):173-179.
[18]Zermann DH,Doggweiler R,Ishigooka M,et al.Male pelvic pain-a neuro-behavioral perspective.Neurourol Urodyn,1998,17:441.
[19]De la Rosette JJ,Karthaus HF,van Kerrebroeck PE,de Boo T,Debruyne FM.Research in 'prostatitis syndromes':the use of alfuzosin(a new alphal-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirrned urodynamic abnormalities.Eur Urol 1992;22:222-227.
[20]Alexander,R.B.,Ponniah,S.,Hasday,J.and Hebel,J.R;Elevated levels of proinfl-ammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome.Urology,1998,52:744-749.
[21]Orhan,I,Onur,R,Ilhan,N.and Ardicoglu,A:Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome,hat J Urol,2001,8:495-501.
[22]Nishimura,T.,Abe,H.,Ito,H.,Ikeda,K.,Oka,E and Yamamoto,M.:IL-lra versus IL-1 levels in prostatic fluid from prostati.tis patients.Urol Int,1998,60:92-96.
[23]Miller,L.J.,Fischer,K.A.,Goralnick,S.J.,Litt,M.,Burleson,J.A.,Albertsen,P.et al:Intefleukin-10 levels in seminal plasma:implications for chronic prostatitis chronic pelvic pain syndrome.J Urol,2002,167:753-759.
[24]Fiorentino,D.E,Bond,M.W.and Mosmann,T.R.:Two types of mouse T helper cell.IV.Th2 clones secrete a factor that inhibits cytokine production by Thl clones.J Exp Med,1989,170:2081-2084.
[25]Baggiolini,M.,Walz,A.and Kunkel,S.L.:Neutrophil-activating peptide- 1/interleukin 8,a novel cytokine that activates neutrophils.J Clin Invest,1989,84:1045-1048.
[26]唐孝达.慢性前列腺炎诊断与治疗进展[J].中国男科学杂志,2002,16(3):193-196.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |